← Leaderboards
Timothy P Cripe
Children'S Hospital Med Ctr (Cincinnati)
$10,144,846
Attributed
$11,324,787
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.4M · FY2006–25$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,978,893 · 16
FDA$408,806 · 1
By mechanism
U54$16,217,500 · 6
R01$2,704,850 · 3
R21$2,246,556 · 5
T32$1,439,449 · 1
P50$619,178 · 1
R29$160,166 · 1
Top collaborators
- Elaine R Mardis5 shared
- Mitchell S. Cairo2 shared
- Dmitri Kudryashov2 shared
- Nancy Ratner2 shared
- Poul H.B. Sorensen2 shared
- Lincoln D Stein2 shared
- Pin Yi Wang2 shared
- Kevin A Cassady1 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsTumorVirusCancer CellOncolyticResponseSimplexvirusBaseClinical TrialsImmuneOncolytic VirusesPharmaceutical PreparationsFutureImmunotherapyMediatingSolid NeoplasmChildhoodDesignRhabdomyosarcomaUniversitiesResistanceSiteImmune Response
Grant awards (48)
A New Paradigm to Prevent and Treat Micrometastases$490,840
R01 · FY2025 · CA · contact PI
Training Program in Basic and Translational Pediatric Oncology Research$389,674
T32 · FY2025 · CA · contact PI
A New Paradigm to Prevent and Treat Micrometastases$504,838
R01 · FY2024 · CA · contact PI
Training Program in Basic and Translational Pediatric Oncology Research$287,283
T32 · FY2024 · CA · contact PI
Training Program in Basic and Translational Pediatric Oncology Research$393,402
T32 · FY2023 · CA · contact PI
Oncolytic virus bispecific gene delivery for high grade gliomas$366,900
U54 · FY2023 · CA · contact PI
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy$366,900
U54 · FY2023 · CA · contact PI
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy$253,700
U54 · FY2023 · CA · contact PI
Novel Immunomodulation and Facilitation of âSuppression Proofâ CAR NK cell against Ewing sarcoma$253,700
U54 · FY2023 · CA · contact PI
Training Program in Basic and Translational Pediatric Oncology Research$369,090
T32 · FY2022 · CA
Core A:Administrative Core$245,000
U54 · FY2022 · CA · contact PI
Overcoming Immunological Tumor Microenvironment Resistance in Ewing Sarcoma$245,000
U54 · FY2022 · CA · contact PI
Childhood high-risk sarcoma derived human satellite (HSAT) and endogenous retroviral (ERV) RNAs in systemic immunosuppression and inflammation$225,752
U54 · FY2022 · CA · contact PI
Admin-Core-001$225,752
U54 · FY2022 · CA · contact PI
Diversity Supplement: Hernandez-Aguirre- Cripe U54$172,073
U54 · FY2022 · CA · contact PI
Admin-Core-001$172,073
U54 · FY2022 · CA · contact PI
IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapy$217,500
U54 · FY2021 · CA · contact PI
Childhood high-risk sarcoma derived human satellite (HSAT) and endogenous retroviral (ERV) RNAs in immunosuppression and inflammation$202,800
U54 · FY2021 · CA · contact PI
An innovative modular strategy for highly specific elimination of human osteosarcomas$201,231
R21 · FY2020 · CA
Improving Lytic Potency of Herpes Virus Cancer Therapeutics$165,300
R21 · FY2020 · CA
Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center$137,060
U54 · FY2020 · CA · contact PI
Core A:Administrative Core$137,060
U54 · FY2020 · CA · contact PI
Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center$10,242,127
U54 · FY2019 · CA · contact PI
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy$1,907,013
U54 · FY2019 · CA · contact PI
Core A:Administrative Core$847,090
U54 · FY2019 · CA · contact PI
Improving Lytic Potency of Herpes Virus Cancer Therapeutics$198,360
R21 · FY2019 · CA
An innovative modular strategy for highly specific elimination of human osteosarcomas$179,916
R21 · FY2019 · CA
CendR peptide-mediated enhancement of systemic oncolytic herpes virotherapy$195,098
R21 · FY2016 · CA · contact PI
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors$379,455
R21 · FY2015 · NS
CendR peptide-mediated enhancement of systemic oncolytic herpes virotherapy$162,491
R21 · FY2015 · CA · contact PI
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors$393,455
R21 · FY2014 · NS
Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006$200,000
R01 · FY2014 · FD · contact PI
Xenograft Core for NF1 Experimental Therapeutics$160,511
P50 · FY2012 · NS · contact PI
Xenograft Core for NF1 Experimental Therapeutics$173,511
P50 · FY2011 · NS · contact PI
Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006$8,806
R01 · FY2011 · FD · contact PI
Oncolytic HSV Therapy in Immunocompetent Sarcoma Models$258,529
R01 · FY2010 · CA · contact PI
Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006$200,000
R01 · FY2010 · FD · contact PI
Xenograft Core for NF1 Experimental Therapeutics$100,115
P50 · FY2010 · NS · contact PI
Oncolytic HSV Therapy in Immunocompetent Sarcoma Models$258,529
R01 · FY2009 · CA · contact PI
Virotherapy for Neuroblastoma Stem Cells$202,500
R21 · FY2009 · CA · contact PI
Xenograft Core for NF1 Experimental Therapeutics$92,714
P50 · FY2009 · NS · contact PI
Oncolytic HSV Therapy in Immunocompetent Sarcoma Models$258,529
R01 · FY2008 · CA · contact PI
Virotherapy for Neuroblastoma Stem Cells$168,750
R21 · FY2008 · CA · contact PI
Xenograft Core for NF1 Experimental Therapeutics$92,327
P50 · FY2008 · NS · contact PI
Oncolytic HSV Therapy in Immunocompetent Sarcoma Models$258,529
R01 · FY2007 · CA · contact PI
Oncolytic HSV Therapy in Immunocompetent Sarcoma Models$266,250
R01 · FY2006 · CA · contact PI
REGULATED TOXIN GENE THERAPY FOR RHABDOMYOSARCOMA$80,719
R29 · FY2001 · CA
REGULATED TOXIN GENE THERAPY FOR RHABDOMYOSARCOMA$79,447
R29 · FY2000 · CA